Publication: Reply to “Tolerogenic insulin peptide therapy precipitates type 1 diabetes”
Loading...
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Rockefeller University Press
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Daniel, Carolin, Benno Weigmann, and Harald von Boehmer. 2017. “Reply to “Tolerogenic insulin peptide therapy precipitates type 1 diabetes”.” The Journal of Experimental Medicine 214 (7): 2157-2159. doi:10.1084/jem.20170285. http://dx.doi.org/10.1084/jem.20170285.
Abstract
In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3+ regulatory T cell conversion.
Description
Other Available Sources
Research Data
Keywords
Reply
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service